Gastric Cancer as Preventable Disease

Massimo Rugge, Robert M. Genta, Francesco Di Mario, Emad M. El-Omar, Hashem B. El-Serag, Matteo Fassan, Richard H. Hunt, Ernst J. Kuipers, Peter Malfertheiner, Kentaro Sugano, David Y. Graham

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Gastric cancer, 1 of the 5 most common causes of cancer death, is associated with a 5-year overall survival rate less than 30%. A minority of cancers occurs as part of syndromic diseases; more than 90% of adenocarcinomas are considered as the ultimate consequence of a longstanding mucosal inflammation. Helicobacter pylori infection is the leading etiology of non-self-limiting gastritis, which may result in atrophy of the gastric mucosa and impaired acid secretion. Gastric atrophy establishes a field of cancerization prone to further molecular and phenotypic changes, possibly resulting in cancer growth. This well-understood natural history provides the clinicopathologic rationale for primary and secondary cancer prevention strategies. A large body of evidence demonstrates that combined primary (H pylori eradication) and secondary (mainly endoscopy) prevention efforts may prevent or limit the progression of gastric oncogenesis. This approach, which is tailored to different country-specific gastric cancer incidence, socioeconomic, and cultural factors, requires that the complementary competences of gastroenterologists, oncologists, and pathologists be amalgamated into a common strategy of health policy.

Original languageEnglish (US)
JournalClinical Gastroenterology and Hepatology
DOIs
StateAccepted/In press - 2017

Fingerprint

Stomach Neoplasms
Atrophy
Neoplasms
Stomach
Pylorus
Helicobacter Infections
Gastritis
Health Policy
Secondary Prevention
Gastric Mucosa
Natural History
Helicobacter pylori
Mental Competency
Endoscopy
Cause of Death
Carcinogenesis
Adenocarcinoma
Survival Rate
Inflammation
Acids

Keywords

  • Gastric Cancer
  • Gastritis
  • Helicobacter pylori
  • Primary Prevention
  • Secondary Prevention

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Rugge, M., Genta, R. M., Di Mario, F., El-Omar, E. M., El-Serag, H. B., Fassan, M., ... Graham, D. Y. (Accepted/In press). Gastric Cancer as Preventable Disease. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2017.05.023

Gastric Cancer as Preventable Disease. / Rugge, Massimo; Genta, Robert M.; Di Mario, Francesco; El-Omar, Emad M.; El-Serag, Hashem B.; Fassan, Matteo; Hunt, Richard H.; Kuipers, Ernst J.; Malfertheiner, Peter; Sugano, Kentaro; Graham, David Y.

In: Clinical Gastroenterology and Hepatology, 2017.

Research output: Contribution to journalArticle

Rugge, M, Genta, RM, Di Mario, F, El-Omar, EM, El-Serag, HB, Fassan, M, Hunt, RH, Kuipers, EJ, Malfertheiner, P, Sugano, K & Graham, DY 2017, 'Gastric Cancer as Preventable Disease', Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2017.05.023
Rugge, Massimo ; Genta, Robert M. ; Di Mario, Francesco ; El-Omar, Emad M. ; El-Serag, Hashem B. ; Fassan, Matteo ; Hunt, Richard H. ; Kuipers, Ernst J. ; Malfertheiner, Peter ; Sugano, Kentaro ; Graham, David Y. / Gastric Cancer as Preventable Disease. In: Clinical Gastroenterology and Hepatology. 2017.
@article{75b12df6a6de40c981f4d3c9596f950c,
title = "Gastric Cancer as Preventable Disease",
abstract = "Gastric cancer, 1 of the 5 most common causes of cancer death, is associated with a 5-year overall survival rate less than 30{\%}. A minority of cancers occurs as part of syndromic diseases; more than 90{\%} of adenocarcinomas are considered as the ultimate consequence of a longstanding mucosal inflammation. Helicobacter pylori infection is the leading etiology of non-self-limiting gastritis, which may result in atrophy of the gastric mucosa and impaired acid secretion. Gastric atrophy establishes a field of cancerization prone to further molecular and phenotypic changes, possibly resulting in cancer growth. This well-understood natural history provides the clinicopathologic rationale for primary and secondary cancer prevention strategies. A large body of evidence demonstrates that combined primary (H pylori eradication) and secondary (mainly endoscopy) prevention efforts may prevent or limit the progression of gastric oncogenesis. This approach, which is tailored to different country-specific gastric cancer incidence, socioeconomic, and cultural factors, requires that the complementary competences of gastroenterologists, oncologists, and pathologists be amalgamated into a common strategy of health policy.",
keywords = "Gastric Cancer, Gastritis, Helicobacter pylori, Primary Prevention, Secondary Prevention",
author = "Massimo Rugge and Genta, {Robert M.} and {Di Mario}, Francesco and El-Omar, {Emad M.} and El-Serag, {Hashem B.} and Matteo Fassan and Hunt, {Richard H.} and Kuipers, {Ernst J.} and Peter Malfertheiner and Kentaro Sugano and Graham, {David Y.}",
year = "2017",
doi = "10.1016/j.cgh.2017.05.023",
language = "English (US)",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Gastric Cancer as Preventable Disease

AU - Rugge, Massimo

AU - Genta, Robert M.

AU - Di Mario, Francesco

AU - El-Omar, Emad M.

AU - El-Serag, Hashem B.

AU - Fassan, Matteo

AU - Hunt, Richard H.

AU - Kuipers, Ernst J.

AU - Malfertheiner, Peter

AU - Sugano, Kentaro

AU - Graham, David Y.

PY - 2017

Y1 - 2017

N2 - Gastric cancer, 1 of the 5 most common causes of cancer death, is associated with a 5-year overall survival rate less than 30%. A minority of cancers occurs as part of syndromic diseases; more than 90% of adenocarcinomas are considered as the ultimate consequence of a longstanding mucosal inflammation. Helicobacter pylori infection is the leading etiology of non-self-limiting gastritis, which may result in atrophy of the gastric mucosa and impaired acid secretion. Gastric atrophy establishes a field of cancerization prone to further molecular and phenotypic changes, possibly resulting in cancer growth. This well-understood natural history provides the clinicopathologic rationale for primary and secondary cancer prevention strategies. A large body of evidence demonstrates that combined primary (H pylori eradication) and secondary (mainly endoscopy) prevention efforts may prevent or limit the progression of gastric oncogenesis. This approach, which is tailored to different country-specific gastric cancer incidence, socioeconomic, and cultural factors, requires that the complementary competences of gastroenterologists, oncologists, and pathologists be amalgamated into a common strategy of health policy.

AB - Gastric cancer, 1 of the 5 most common causes of cancer death, is associated with a 5-year overall survival rate less than 30%. A minority of cancers occurs as part of syndromic diseases; more than 90% of adenocarcinomas are considered as the ultimate consequence of a longstanding mucosal inflammation. Helicobacter pylori infection is the leading etiology of non-self-limiting gastritis, which may result in atrophy of the gastric mucosa and impaired acid secretion. Gastric atrophy establishes a field of cancerization prone to further molecular and phenotypic changes, possibly resulting in cancer growth. This well-understood natural history provides the clinicopathologic rationale for primary and secondary cancer prevention strategies. A large body of evidence demonstrates that combined primary (H pylori eradication) and secondary (mainly endoscopy) prevention efforts may prevent or limit the progression of gastric oncogenesis. This approach, which is tailored to different country-specific gastric cancer incidence, socioeconomic, and cultural factors, requires that the complementary competences of gastroenterologists, oncologists, and pathologists be amalgamated into a common strategy of health policy.

KW - Gastric Cancer

KW - Gastritis

KW - Helicobacter pylori

KW - Primary Prevention

KW - Secondary Prevention

UR - http://www.scopus.com/inward/record.url?scp=85021967442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021967442&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2017.05.023

DO - 10.1016/j.cgh.2017.05.023

M3 - Article

C2 - 28532700

AN - SCOPUS:85021967442

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

ER -